Dr. Michael Evans was recently awarded a research grant that aims to develop new drugs to more effectively treat or eliminate tuberous sclerosis complex, or TSC. The research team has developed an innovative strategy that will allow them to screen for antibody fragments specific for cells lacking TSC1 or TSC2.